利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.014 秒)

    ACYL-COA DEHYDROGENASE ASSAYS
    3.
    发明公开
    ACYL-COA DEHYDROGENASE ASSAYS 审中-公开
    ACYL-COA脱氢酶测定

    公开(公告)号：EP2914736A1

    公开(公告)日：2015-09-09

    申请号：EP13852305.5

    申请日：2013-10-30

    申请人： Advanced Liquid Logic, Inc.

    发明人： FOEGEDING, Nora, J. ,  GRAHAM, Carrie, A. ,  ECKHARDT, Allen, E.

    IPC分类号： C12Q1/32 ,  C12Q1/26 ,  G01N33/48

    CPC分类号： C12Q1/32 ,  G01N33/6893 ,  G01N2333/90206 ,  G01N2800/04 ,  G01N2800/7085

    摘要： A method for conducting medium-chain acyl-CoA dehydrogenase (MCAD) and very- long-chain acyl-CoA dehydrogenase (VCAD) enzymatic activity assays is provided. The method may include, but is not limited to, preparing a sample; preparing an enzyme- specific substrate/reagent mixture; mixing an aliquot of the prepared sample with an aliquot of the enzyme-specific substrate/reagent mixture; reading absorbance in the range of about 600 nm; incubating the prepared sample and enzyme-specific substrate/reagent mixture; and reading absorbance in the range of about 600 nm at various time intervals.

    摘要翻译： 提供了用于进行中链酰基-CoA脱氢酶（MCAD）和超长链酰基-CoA脱氢酶（VCAD）酶活性测定的方法。 该方法可以包括但不限于准备样品; 制备酶特异性底物/试剂混合物; 将制备的样品的等分试样与等份的酶特异性底物/试剂混合物混合; 读取约600nm范围内的吸光度; 温育制备的样品和酶特异性底物/试剂混合物; 并以不同的时间间隔读取约600nm范围内的吸光度。

    BIOMARKERS
    5.
    发明公开
    BIOMARKERS 审中-公开
    生物标记物

    公开(公告)号：EP3004889A1

    公开(公告)日：2016-04-13

    申请号：EP14726744.7

    申请日：2014-05-22

    申请人： King's College London

    发明人： MAYR, Manuel

    IPC分类号： G01N33/68 ,  G01N33/92

    CPC分类号： G01N33/6887 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/02 ,  G01N2800/7085

    摘要： in one aspect., the present Invention provides a method of determining cardiovascular disease (CVD) risk in a subject comprising (a) determining fatty acid composition of lipids In a sample obtained from the subject, wherein the lipids are selected from the group consisting of: (I) triacylgiycerols (TAGs); and cholesterol esters (CEs); and (b) comparing the fatty acid composition of the lipids in the sample from the subject to a control; wherein a decrease in mean fatty acid chain length in the lipids in the sample from the subject compared to the control indicates an. increased risk of CVD in the subject; and wherein the. CVD is associated with atherosclerotic plaque rupture or thrombosis., and/or the CVD Is an acute ischemic event selected from myocardial infarction, ischemic stroke or sudden cardiac death.

    摘要翻译： 在一个方面，本发明提供了一种测定受试者心血管疾病（CVD）风险的方法，包括（a）测定脂质的脂肪酸组成在从受试者获得的样品中，其中脂质选自 ：（I）三酰基胆汁醇（TAG）; 和胆固醇酯（CE）; 和（b）将来自受试者的样品中的脂质的脂肪酸组成与对照相比较; 其中与对照相比，来自受试者的样品中脂质中平均脂肪酸链长度的降低表示a。 受试者CVD风险增加; 并且其中。 CVD与动脉粥样硬化斑块破裂或血栓形成有关，和/或CVD是选自心肌梗塞，缺血性卒中或心源性猝死的急性缺血事件。

    BIOMARKERS OF DE NOVO LIPOGENESIS AND METHODS USING THE SAME
    7.
    发明授权
    BIOMARKERS OF DE NOVO LIPOGENESIS AND METHODS USING THE SAME 有权

    公开(公告)号：EP3082833B1

    公开(公告)日：2018-12-05

    申请号：EP14870759.9

    申请日：2014-12-18

    申请人： Metabolon, Inc.

    发明人： WATKINS, Steven M.

    IPC分类号： G01N33/92

    CPC分类号： G01N33/92 ,  G01N2405/00 ,  G01N2800/7085

    摘要： Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression/regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.

    BIOMARKERS OF DE NOVO LIPOGENESIS AND METHODS USING THE SAME
    8.
    发明公开
    BIOMARKERS OF DE NOVO LIPOGENESIS AND METHODS USING THE SAME 有权
    生物标记脂肪酸从头合成和程序

    公开(公告)号：EP3082833A1

    公开(公告)日：2016-10-26

    申请号：EP14870759.9

    申请日：2014-12-18

    申请人： Metabolon, Inc.

    发明人： WATKINS, Steven M.

    IPC分类号： A61K35/60 ,  A61P35/04 ,  G01N33/50

    CPC分类号： G01N33/92 ,  G01N2405/00 ,  G01N2800/7085

    摘要： Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression/regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.

    METHOD FOR REMOVAL OF TRIGLYCERIDES IN LIPOPROTEINS OTHER THAN LOW-DENSITY LIPOPROTEINS
    9.
    发明公开
    METHOD FOR REMOVAL OF TRIGLYCERIDES IN LIPOPROTEINS OTHER THAN LOW-DENSITY LIPOPROTEINS 审中-公开
    PROCESS FOR LDL以外的脂蛋白中的甘油三酯拆除

    公开(公告)号：EP2840145A4

    公开(公告)日：2015-12-23

    申请号：EP13777616

    申请日：2013-04-19

    申请人： DENKA SEIKEN KK

    发明人： OHTA MOTOKO

    IPC分类号： C12Q1/44 ,  C12Q1/26 ,  C12Q1/48 ,  C12Q1/61 ,  G01N33/68 ,  G01N33/92

    CPC分类号： C07K1/14 ,  C12Q1/26 ,  C12Q1/44 ,  C12Q1/485 ,  C12Q1/61 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/7085

    摘要： Disclosed is a method for selectively eliminating triglycerides in lipoproteins other than low density lipoprotein, which method allows one to provide a method for directly and differentially quantifying LDL-TG in a sample with excellent simplicity, specificity and accuracy using an automated analyzer or the like without performing a laborious operation of pretreatment such as centrifugation or electrophoresis. The method for eliminating triglycerides in lipoproteins other than low density lipoproteins includes allowing lipoprotein lipase, cholesterol esterase, glycerol kinase and glycerol-3-phosphate oxidase to act on a sample in the presence of a surfactant that acts on lipoproteins other than low density lipoprotein and/or a surfactant having LDL-protecting action, and eliminating hydrogen peroxide produced thereby.